Last updated: 2026-09-28 23:53:20. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
SL Science Holding Limited (SLBT) operates in the -- sector and is listed on NASDAQ. The stock is currently priced at $1,93, with a market capitalization of $880,39M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1,42 to $14,50. This page covers its latest market performance, valuation, price trends and company information.
$880,39M | |
$1,63 | |
$53,95 | |
$1,42 | |
$1,57 | |
274,11K | |
122,85K | |
-- | |
$14,50 | |
$1,42 | |
-- | |
-- |
SL Science Holding Limited (SLBT) is trading at $1,83 in after-hours trading as of 2026-09-28 23:46:00, up 16,56% ($0,26) from the regular-session close of $1,57.
After-hours trading shows how investors are pricing SLBT after the regular session closes. The current after-hours price is above the regular-session close, indicating positive after-hours sentiment.
Over the past seven days, SL Science Holding Limited (SLBT) moved from $1,87 to $1,93, representing a gain of 2,94% ($0,05).
The stock traded between $1,42 and $1,98 during the period. The latest price is near the upper end of the 7-day range, indicating moderate upward.
The average daily volume was 84,54 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 3,9%
SLBT is currently trading at $1,93, placing it 3,9% of the way from its 52-week low of $1,42 to its 52-week high of $14,50. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
SL Science Holding Ltd is a biomedical company specialized in developing cellular and gene therapies advancing regenerative medicine and cancer treatment. It utilizes immune stem cells to target cancer and bovine-derived milk exosomes to regenerate damaged tissues, thus potentially offering expansive medical applications for its products. With proprietary technologies such as Armed-T and Gamma Delta T cells, as well as exosome applications in skincare and cancer recovery. It operates in three segments namely Exosome products, CD-19 Armed-T products, and GDT cell therapy products. It derives revenue from Exosome products segment.
| Employees | 20 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of SL Science Holding Limited (SLBT) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.